Shopping Cart 0
Cart Subtotal
USD 0

Cytodyn Inc (CYDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products pipeline include PRO 140, Cytofeline and Cytolin. Cytodyn's PRO 140 is a viral-entry inhibitor intended to protect healthy cells from viral infection which blocks the HIV co-receptor C-C chemokine receptor type 5 (CCR5) on T-cells. Cytofeline, a anti-LFA-1 antibody is used for the treatment of FIV infection. Cytolin is a mouse monoclonal antibody developed to identify a immune cell called cytotoxic T cell (CTL). Cytodyn is headquartered in Vancouver, Washington, the US.

Cytodyn Inc (CYDY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cytodyn Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12

Venture Financing 14

ProstaGene Raises USD0.4 Million in Financing 14

Cytodyn Raises USD2.7 million in Financing Round 15

CytoDyn Raises USD3.3 million in Venture Financing Round 16

ProstaGene Raises USD0.4 Million in Venture Financing 17

Partnerships 18

CytoDyn Amends Research Agreement with Drexel University College of Medicine 18

Licensing Agreements 19

CytoDyn Enters into Licensing Agreement with Lonza Sales 19

Equity Offering 20

CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20

CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21

CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22

CytoDyn Raises USD1.2 Million in Private Placement of Shares 23

CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24

CytoDyn Raises USD4.3 Million in Private Placement of Shares 25

CytoDyn Raises USD7.3 Million in Private Placement of Shares 26

CytoDyn Completes Final Tranche Of Private Placement Of Units For USD 6.7 Million 27

CytoDyn Raises USD14.5 Million in Private Placement of Units 28

CytoDyn Completes Private Placement Of Shares For USD 0.6 Million 29

Debt Offering 30

CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30

CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31

CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32

Cytodyn Completes Private Placement Of Notes For USD 3.7 Million 33

Acquisition 34

CytoDyn to Acquires ProstaGene 34

Cytodyn Inc-Key Competitors 35

Cytodyn Inc-Key Employees 36

Cytodyn Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Corporate Communications 38

Jan 30, 2017: CytoDyn appoints executive chairman 38

Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 39

Product News 40

12/07/2017: Independent Data Monitoring Committee Recommends Continuation of CytoDyn's PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint 40

08/21/2017: CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 41

08/09/2017: CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial 42

07/12/2018: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders 43

07/12/2018: CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders 45

06/11/2018: CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA 47

06/09/2018: Weekly Injections of CytoDyns PRO 140 in Combination with Optimized Antiretroviral Treatment Shows Long-Acting HIV-1 Viral Suppression 48

06/04/2018: Results from CytoDyn's Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 49

06/01/2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 50

04/11/2018: CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 51

04/11/2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 52

03/29/2018: CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders 53

02/20/2018: CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection 54

01/30/2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 56

Product Approvals 57

Jun 22, 2018: CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy 57

Mar 14, 2018: CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD 58

Oct 13, 2017: CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA 59

Oct 05, 2017: CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease 60

Sep 06, 2017: CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 61

Apr 17, 2017: Potential for CytoDyn's PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 62

Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 63

Clinical Trials 64

Jul 30, 2018: Cytodyn announces significantly improved response rate at higher dose of PRO 140 in HIV phase 3 monotherapy trial 64

Jul 16, 2018: CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial 66

Jun 26, 2018: New Research Supports Potential for CytoDyn's PRO 140 to Inhibit Breast Cancer Metastasis 67

Jun 20, 2018: CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD 68

May 24, 2018: Results of CytoDyns PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials 69

Nov 14, 2017: CytoDyn's PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation 70

May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 71

Feb 14, 2017: Two-Year Update From CytoDyn's PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73


List Of Figure

List of Figures

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cytodyn Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytodyn Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12

ProstaGene Raises USD0.4 Million in Financing 14

Cytodyn Raises USD2.7 million in Financing Round 15

CytoDyn Raises USD3.3 million in Venture Financing Round 16

ProstaGene Raises USD0.4 Million in Venture Financing 17

CytoDyn Amends Research Agreement with Drexel University College of Medicine 18

CytoDyn Enters into Licensing Agreement with Lonza Sales 19

CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20

CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21

CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22

CytoDyn Raises USD1.2 Million in Private Placement of Shares 23

CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24

CytoDyn Raises USD4.3 Million in Private Placement of Shares 25

CytoDyn Raises USD7.3 Million in Private Placement of Shares 26

CytoDyn Completes Final Tranche Of Private Placement Of Units For USD 6.7 Million 27

CytoDyn Raises USD14.5 Million in Private Placement of Units 28

CytoDyn Completes Private Placement Of Shares For USD 0.6 Million 29

CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30

CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31

CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32

Cytodyn Completes Private Placement Of Notes For USD 3.7 Million 33

CytoDyn to Acquires ProstaGene 34

Cytodyn Inc, Key Competitors 35

Cytodyn Inc, Key Employees 36

Cytodyn Inc, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cytodyn Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products pipeline include PRO 140, Cytofeline and Cytolin. Cytodyn's PRO 140 is a viral-entry inhibitor intended to protect healthy cells from viral infection which blocks the HIV co-receptor C-C chemokine receptor type 5 (CCR5) on T-cells. Cytofeline, a anti-LFA-1 antibody is used for the treatment of FIV infection. Cytolin is a mouse monoclonal antibody developed to identify a immune cell called cytotoxic T cell (CTL). Cytodyn is headquartered in Vancouver, Washington, the US.

Cytodyn Inc (CYDY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cytodyn Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12

Venture Financing 14

ProstaGene Raises USD0.4 Million in Financing 14

Cytodyn Raises USD2.7 million in Financing Round 15

CytoDyn Raises USD3.3 million in Venture Financing Round 16

ProstaGene Raises USD0.4 Million in Venture Financing 17

Partnerships 18

CytoDyn Amends Research Agreement with Drexel University College of Medicine 18

Licensing Agreements 19

CytoDyn Enters into Licensing Agreement with Lonza Sales 19

Equity Offering 20

CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20

CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21

CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22

CytoDyn Raises USD1.2 Million in Private Placement of Shares 23

CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24

CytoDyn Raises USD4.3 Million in Private Placement of Shares 25

CytoDyn Raises USD7.3 Million in Private Placement of Shares 26

CytoDyn Completes Final Tranche Of Private Placement Of Units For USD 6.7 Million 27

CytoDyn Raises USD14.5 Million in Private Placement of Units 28

CytoDyn Completes Private Placement Of Shares For USD 0.6 Million 29

Debt Offering 30

CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30

CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31

CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32

Cytodyn Completes Private Placement Of Notes For USD 3.7 Million 33

Acquisition 34

CytoDyn to Acquires ProstaGene 34

Cytodyn Inc-Key Competitors 35

Cytodyn Inc-Key Employees 36

Cytodyn Inc-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Corporate Communications 38

Jan 30, 2017: CytoDyn appoints executive chairman 38

Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 39

Product News 40

12/07/2017: Independent Data Monitoring Committee Recommends Continuation of CytoDyn's PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint 40

08/21/2017: CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 41

08/09/2017: CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial 42

07/12/2018: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders 43

07/12/2018: CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders 45

06/11/2018: CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA 47

06/09/2018: Weekly Injections of CytoDyns PRO 140 in Combination with Optimized Antiretroviral Treatment Shows Long-Acting HIV-1 Viral Suppression 48

06/04/2018: Results from CytoDyn's Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 49

06/01/2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 50

04/11/2018: CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 51

04/11/2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 52

03/29/2018: CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders 53

02/20/2018: CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection 54

01/30/2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 56

Product Approvals 57

Jun 22, 2018: CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy 57

Mar 14, 2018: CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD 58

Oct 13, 2017: CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA 59

Oct 05, 2017: CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease 60

Sep 06, 2017: CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 61

Apr 17, 2017: Potential for CytoDyn's PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 62

Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 63

Clinical Trials 64

Jul 30, 2018: Cytodyn announces significantly improved response rate at higher dose of PRO 140 in HIV phase 3 monotherapy trial 64

Jul 16, 2018: CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial 66

Jun 26, 2018: New Research Supports Potential for CytoDyn's PRO 140 to Inhibit Breast Cancer Metastasis 67

Jun 20, 2018: CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD 68

May 24, 2018: Results of CytoDyns PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials 69

Nov 14, 2017: CytoDyn's PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation 70

May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 71

Feb 14, 2017: Two-Year Update From CytoDyn's PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73


List Of Figure

List of Figures

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Cytodyn Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cytodyn Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10

Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12

ProstaGene Raises USD0.4 Million in Financing 14

Cytodyn Raises USD2.7 million in Financing Round 15

CytoDyn Raises USD3.3 million in Venture Financing Round 16

ProstaGene Raises USD0.4 Million in Venture Financing 17

CytoDyn Amends Research Agreement with Drexel University College of Medicine 18

CytoDyn Enters into Licensing Agreement with Lonza Sales 19

CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20

CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21

CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22

CytoDyn Raises USD1.2 Million in Private Placement of Shares 23

CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24

CytoDyn Raises USD4.3 Million in Private Placement of Shares 25

CytoDyn Raises USD7.3 Million in Private Placement of Shares 26

CytoDyn Completes Final Tranche Of Private Placement Of Units For USD 6.7 Million 27

CytoDyn Raises USD14.5 Million in Private Placement of Units 28

CytoDyn Completes Private Placement Of Shares For USD 0.6 Million 29

CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30

CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31

CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32

Cytodyn Completes Private Placement Of Notes For USD 3.7 Million 33

CytoDyn to Acquires ProstaGene 34

Cytodyn Inc, Key Competitors 35

Cytodyn Inc, Key Employees 36

Cytodyn Inc, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cytodyn Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.